Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for individuals two years of age or older.

Longboard’s leadership team will be joined by key opinion leaders in the DEE space, including Dennis Dlugos, MD, MSCE, pediatric neurologist at Children’s Hospital of Philadelphia, Vice President & Officer of the Epilepsy Study Consortium, and Principal Investigator of Longboard’s Phase 1b/2a PACIFIC Study, and Ilene Penn Miller, JD, LLM, Director, Rare Epilepsy Network (REN).

A live question and answer session will follow the formal presentations.

EVENT DETAILS:

WHEN: Monday, September 16, 2024 | 10 AM – noon ET WHERE: Cooley LLP, 55 Hudson Yards, New York, NY 10001 REGISTRATION LINK (both in-person & virtual*): https://lifescievents.com/event/longboardpharma/

*In-person attendance is limited to invited research analysts and institutional investors only. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Longboard’s website at https://www.longboardpharma.com/. The archived webcast will be available for at least 30 days following the event.

ABOUT LONGBOARD PHARMACEUTICALS

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Earlier this year, Longboard reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants with DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. Longboard recently completed a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Bexicaserin and LP659 are investigational compounds that are not approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “focus”, “will”, “upcoming”, “working to”, “designed to”, “plans”, “potential” or the negative, plural or other tenses of these words, references to future dates or time periods, or other comparable language, and they may include, without limitation, statements about Longboard’s upcoming Investor and Analyst Event, product candidates, clinical and preclinical programs, focus and work. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

CORPORATE CONTACT: Megan E. Knight VP, Head of Investor Relations IR@longboardpharma.com 858.789.9283

Longboard Pharmaceuticals (NASDAQ:LBPH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Longboard Pharmaceuticals
Longboard Pharmaceuticals (NASDAQ:LBPH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Longboard Pharmaceuticals